Last reviewed · How we verify
MabThera
MabThera is a CD20-targeting monoclonal antibody Biologic drug developed by Sandoz. It is currently FDA-approved for Relapsed or refractory B-cell non-Hodgkin's lymphoma, Chronic lymphocytic leukemia (CLL), Rheumatoid arthritis. Also known as: EU-Rituximab, Rituximab, rituximab, Reference rituximab.
MabThera (rituximab) is a monoclonal antibody that binds to CD20 on B cells, triggering their destruction through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
MabThera (rituximab) is a monoclonal antibody that binds to CD20 on B cells, triggering their destruction through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Used for Non-Hodgkin's lymphoma (CD20-positive B-cell), Chronic lymphocytic leukemia (CLL), Rheumatoid arthritis.
At a glance
| Generic name | MabThera |
|---|---|
| Also known as | EU-Rituximab, Rituximab, rituximab, Reference rituximab |
| Sponsor | Sandoz |
| Drug class | CD20-targeting monoclonal antibody |
| Target | CD20 |
| Modality | Biologic |
| Therapeutic area | Oncology, Immunology |
| Phase | FDA-approved |
Mechanism of action
Rituximab targets the CD20 antigen expressed on the surface of B lymphocytes. By binding to CD20, it recruits immune effector cells and complement to eliminate B cells, reducing autoimmune responses or malignant B-cell populations. This mechanism is effective in both hematologic malignancies and autoimmune diseases where B cells play a pathogenic role.
Approved indications
- Relapsed or refractory B-cell non-Hodgkin's lymphoma
- Chronic lymphocytic leukemia (CLL)
- Rheumatoid arthritis
- Granulomatosis with polyangiitis (GPA)
- Microscopic polyangiitis (MPA)
Common side effects
- Infusion reactions
- Infections
- Cytopenias (anemia, thrombocytopenia, neutropenia)
- Fatigue
- Fever
- Nausea
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
- Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia (PHASE1, PHASE2)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial (PHASE2)
- Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma (PHASE2)
- Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MabThera CI brief — competitive landscape report
- MabThera updates RSS · CI watch RSS
- Sandoz portfolio CI
Frequently asked questions about MabThera
What is MabThera?
How does MabThera work?
What is MabThera used for?
Who makes MabThera?
Is MabThera also known as anything else?
What drug class is MabThera in?
What development phase is MabThera in?
What are the side effects of MabThera?
What does MabThera target?
Related
- Drug class: All CD20-targeting monoclonal antibody drugs
- Target: All drugs targeting CD20
- Manufacturer: Sandoz — full pipeline
- Therapeutic area: All drugs in Oncology, Immunology
- Indication: Drugs for Relapsed or refractory B-cell non-Hodgkin's lymphoma
- Indication: Drugs for Chronic lymphocytic leukemia (CLL)
- Indication: Drugs for Rheumatoid arthritis
- Also known as: EU-Rituximab, Rituximab, rituximab, Reference rituximab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing